Michel Lagarde, President and CEO of West Pharmaceutical Services Inc, filed a Form 4 on September 10, 2026, disclosing the acquisition of stock options and restricted stock units granted on September 8, 2026.

Key Highlights

  • Reporting person: Michel Lagarde, identified as President and CEO and Director of West Pharmaceutical Services Inc (NYSE:WST).
  • Stock options granted: Three separate stock option awards totaling 37,048 shares of common stock, each with an exercise price of $337.75 and an expiration date of September 8, 2036.
  • Restricted stock units granted: Three separate RSU awards totaling 14,750 units, each representing a contingent right to receive one share of WST common stock.
  • Four-year vesting: Two option awards (13,879 and 11,081 shares) and two RSU awards (6,200 and 4,950 units) vest in four equal annual installments beginning September 8, 2027.
  • Cliff vesting: One option award (12,088 shares) and one RSU award (3,600 units) cliff vest on September 8, 2031.
  • Price of derivative securities: All derivative securities were acquired at a price of $0, according to the filing.

Michel Lagarde's September 2026 Equity Award Details at West Pharmaceutical Services

According to the Form 4 filed on September 10, 2026, Michel Lagarde acquired six derivative security awards on September 8, 2026, all held directly. The filing covers transactions in Table II only, with no non-derivative securities reported in Table I.

The three stock option awards, each structured as a "Right to Buy" common stock, carry an exercise price of $337.75 per share and expire on September 8, 2036. Two of these awards, covering 13,879 and 11,081 shares respectively, vest in four equal annual installments beginning September 8, 2027. The third award, covering 12,088 shares, cliff vests on September 8, 2031. Following the reported transactions, Lagarde beneficially owns 13,879, 11,081, and 12,088 stock options directly, corresponding to each award.

The three restricted stock unit awards, as described in the filing, each represent "a contingent right to receive one share of WST common stock." Two RSU grants, for 6,200 and 4,950 units respectively, vest in four equal annual installments beginning September 8, 2027. A third RSU grant for 3,600 units cliff vests on September 8, 2031. The filing was signed by Louis Lalli "as an agent for Michel Lagarde" on September 10, 2026.

What Was Disclosed

The filing disclosed six equity awards granted to Michel Lagarde, President and CEO of West Pharmaceutical Services Inc (NYSE:WST), on September 8, 2026, consisting of stock options to purchase a total of 37,048 shares and restricted stock units totaling 14,750 units, all held directly.